Remission and outcome
| Characteristic . | All patients, N = 152 . |
|---|---|
| Median number cycles gilteritinib (range) | 4 (1-30) |
| Best response | |
| CR | 31 (21%) |
| CRi | 13 (8.9%) |
| MLFS | 12 (8.2%) |
| PR | 42 (29%) |
| Refractory disease | 39 (27%) |
| Death before response assessment | 9 (6.2%) |
| Missing | 6 |
| Allogeneic transplant | 36 (24%) |
| Bridged directly to transplant with gilteritinib | 16 (11%) |
| Transplant after additional therapy to deepen response | 9 (5.9%) |
| Transplant after relapse/refractory disease | 11 (7.2%) |
| Survival | |
| Day-30 mortality | 1% |
| Day-60 mortality | 10.6% |
| 12-mo survival | 38% (95% CI, 30-47) |
| Median survival (mo) | 9.5 (95% CI, 7.7-11.3) |
| Characteristic . | All patients, N = 152 . |
|---|---|
| Median number cycles gilteritinib (range) | 4 (1-30) |
| Best response | |
| CR | 31 (21%) |
| CRi | 13 (8.9%) |
| MLFS | 12 (8.2%) |
| PR | 42 (29%) |
| Refractory disease | 39 (27%) |
| Death before response assessment | 9 (6.2%) |
| Missing | 6 |
| Allogeneic transplant | 36 (24%) |
| Bridged directly to transplant with gilteritinib | 16 (11%) |
| Transplant after additional therapy to deepen response | 9 (5.9%) |
| Transplant after relapse/refractory disease | 11 (7.2%) |
| Survival | |
| Day-30 mortality | 1% |
| Day-60 mortality | 10.6% |
| 12-mo survival | 38% (95% CI, 30-47) |
| Median survival (mo) | 9.5 (95% CI, 7.7-11.3) |